MannKind/$MNKD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About MannKind
MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
- Ticker
- $MNKD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 592
- Headquarters
- Danbury, United States
- Website
- mannkindcorp.com
MannKind Metrics
BasicAdvanced
$1B
-
-$0.16
1.10
-
Price and volume
Market cap
$1B
Beta
1.1
52-week high
$6.51
52-week low
$2.23
Average daily volume
4.7M
Financial strength
Current ratio
1.719
Quick ratio
1.287
Long term debt to equity
-6.269
Total debt to equity
-6.456
Interest coverage (TTM)
0.15%
Profitability
EBITDA (TTM)
19.535
Gross margin (TTM)
75.39%
Net profit margin (TTM)
-11.08%
Operating margin (TTM)
1.85%
Effective tax rate (TTM)
10.36%
Revenue per employee (TTM)
$660,000
Management effectiveness
Return on assets (TTM)
0.79%
Return on equity (TTM)
71.36%
Valuation
Price to revenue (TTM)
2.2
Price to book
-14.44
Price to tangible book (TTM)
-2.15
Price to free cash flow (TTM)
-47.752
Free cash flow yield (TTM)
-2.09%
Free cash flow per share (TTM)
-0.066
Growth
Revenue change (TTM)
30.45%
Earnings per share change (TTM)
-245.69%
3-year revenue growth (CAGR)
35.53%
3-year earnings per share growth (CAGR)
-4.94%
10-year earnings per share growth (CAGR)
-28.09%
What the Analysts think about MannKind
Analyst ratings (Buy, Hold, Sell) for MannKind stock.
Analyst projections of the future price of MannKind stock.
Bulls say / Bears say
Furoscix sales reached $22.2 million in Q2 and rose 43% from Q1; FDA approval of the ReadyFlow autoinjector gives MannKind a new format to support further growth. (GlobeNewswire)
FDA approval lets Afrezza be used by children aged six and older, widening its potential market, and one-third of the top 100 paediatric insulin prescribers had already prescribed it. (GlobeNewswire)
Nintedanib DPI’s Phase 1b study in idiopathic pulmonary fibrosis met its safety and tolerability goal, with no serious adverse events or treatment discontinuations reported; a Phase 2 study is under way. (OINDPnews)
Revenue growth has not yet produced consistent profits: MannKind reported a $19 million Q2 net loss and a $35.7 million loss for the first half, compared with a first-half profit a year earlier. (StockTitan)
The balance sheet leaves limited room for setbacks: at June-end, MannKind had a $319.1 million term loan, $799.5 million in total liabilities and a $67.2 million stockholders’ deficit. (StockTitan)
Afrezza sales fell 7% year on year in Q2 to $17.0 million, a setback for its core diabetes franchise even as the paediatric indication opens up a new potential market. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2026.
MannKind Financial Performance
Revenues and expenses
MannKind Earnings Performance
Company profitability
Upcoming events
No upcoming events
MannKind News
AllArticlesVideos
Funds containing MannKind
AllUSDGBPEUR
Fund name | Fund size | $MNKD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.